Active components Sofosbuvir and Ledipasvir belong to the category of antiviral medicines used for the treatment of chronic viral hepatitis C.

Pharmaceutical companies located in the United States, Gilead Sciences, Inc. produce the original antiviral medicine containing the drug Ledipasvir and Sofosbuvir. In addition, Indian medicines manufacturers are involved in the serial production of licensed generics such as MyHep-LVIR and other.

When a doctor prescribes a hepatitis medicine "Ledipasvir Sofosbuvir", this means that the patient needs a non-heterferon treatment for chronic hepatitis C. Original medicine is not an inexpensive option, but its generic version is affordable.

In order to better understand the meaning of the functioning of this treatment from a serious virus - Hepatitis C of the 1st and 4th genotypes. The main property of the tablets is to block the replication (uncontrolled reproduction) of dangerous viral cells. The combination of the two active components in the drug complex is as follows:

• Sofosbuvir - serves as a blocker of the viral enzyme NS5B.
• Ledipasvir - serves as a blocker of the protein of the viral microorganism NS5A.

The use of the medicine is strictly according to the doctor's prescription.

The instruction for the use of MyHep-LVIR (Ledipasvir & Sofosbuvir) is quite simple - it is enough to take one tablet once a day. Do not change the dose, if there are no serious side reflexes and reactions of the body. In case of complications, immediately consult a doctor. Reception should be carried out in three ways:

• on an empty stomach;
• in the middle of a meal;
• after meal.
• In many respects, the way of taking the medicine will depend on the choice of the doctor, who tracks all the characteristics of the organism of each patient individually.